For personal use only

Clover Corporation Limited
ABN 85 003 622 866

ASX ANNOUNCEMENT **18 November 2025**

AGM - The Chairman's Address

Dear Shareholders,

FY25 was a strong year for Clover Corporation, and as many of you will recognise, a tale of two halves.

The first half reflected the steady demand levels we experienced through the second half of FY24, with revenue of $37.6m. The second half saw a strong uplift, with sales of $48.4m driven by improved orders from our Human Nutrition customers. We had a particularly strong final quarter, with $4m in orders brought forward as customers worked to meet demand for new product launches.

This turnaround demonstrates the resilience of our business and the value of our diversification strategy. The combination of stronger sales, improved gross margins, and disciplined cost management allowed us to strengthen our balance sheet and continue reducing debt through the year.

Across the year, Clover achieved another step forward in performance.

In Ecuador, the commissioning of our fish oil extraction facility has been successful, producing excellent-quality crude oil and delivering secure supply and cost benefits to Clover and our partners. There remains significant room to further improve throughput, with cost and yield benefits to contribute to further improvement in our gross margin.

For personal use only

At Melody Dairies, we recorded our first full year of profit, a significant milestone driven by better planning, longer production runs of new products and consistent dryer uptime. While the facility is now operating close to capacity, we expect further efficiency gains and margin improvements as product mix continues to evolve.

At our Australian refinery in Melbourne, operations continued to perform reliably, ensuring a consistent supply of quality oils. While incremental margin gains from this refinery will be modest, it remains an essential part of our vertically integrated supply chain.

We remain focused on managing input costs, particularly energy, as we scale our manufacturing footprint and prepare for future expansion.

The return to normalised sales in FY25, combined with strong manufacturing performance, placed the Company in a solid position to continue reducing debt.

Clover continues to drive growth by expediting the commercialisation of innovative products.

Our new distributor model is progressing well, expanding our reach across North America, Asia, and Europe. FY26 will be an important year to demonstrate the benefits of this approach, not just through sales growth, but through new product launches and customer and market diversification.

The CholineXcel project remains one of our most promising innovation programs. This free-flowing powder offers a new revenue stream for Clover, targeting both infant formula where Choline is mandated, and prenatal products where it is used as an essential nutrient. Patent applications are progressing, with customer research and development trials progressing positively. To support expected demand, we are exploring a range of solutions including joint ventures or outright purchase of an additional dryer.

Our encapsulated powders and Gelphorm products continue to advance through customer trials in high-value nutraceutical markets. These are longer-lead opportunities, requiring shelf-life testing and regulatory approvals, but they represent meaningful medium-term growth potential.

We are also progressing regulatory approval for Premneo in Australia/New Zealand and Europe. A second round of trial results is under expert review, an essential step to obtain regulatory approval and to pave the way for market entry.

In my address last year, I said we expected a return to normalised revenue patterns in FY25, and I'm pleased to report that this has been achieved. The final quarter of FY25 delivered record sales, and as a result we experienced a relatively slow start in the new financial year. However, I am pleased to report trading is now showing continued growth and steady order flow. As a result, we expect revenues for 1H FY26 to exceed those for the same period in the prior year.

On behalf of the Board of Directors, I extend my sincere thanks to shareholders for your continued support, and to our employees and management for their dedication and commitment throughout the year.

Rupert Harrington
Chairman

For personal use only